Virion Therapeutics press release
Virion Therapeutics reports broad and sustained anti-HBV immunity following a single VRON-0200 dose in the majority of chronically HBV-infected patients from its Phase 1b study at CROI 2026
Virion Therapeutics announced at CROI 2026 that a single intramuscular dose of VRON-0200, its novel, first-in-class, immunotherapy for HBV functional cure was able to “spark” and re-awaken durable HBV-specific immunity in the majority of chronically HBV-infected patients – with HBsAg declines that were sustained or deepened through Day 360. These data, presented as a late breaker presentation, also highlighted VRON-0200’s ongoing favorable safety and tolerability profile, and its rapid and profound synergy when combined with antigen lowering antiviral agents.
Aligos Therapeutics press release
Aligos Therapeutics presents positive data at CROI 2026
Aligos Therapeutics announced positive data from two presentations at CROI 2026. The pevifoscorvir sodium presentation highlighted the Phase 1 monotherapy study of pevifoscorvir sodium, a potent CAM-E under development for the treatment of chronic hepatitis B virus (HBV) infection. Additionally, the ALG-097558 presentation (ALG-097558: Potential best-in-class ritonavir-free small molecule pan-coronavirus protease inhibitor) showcased data from participants with hepatic and renal impairment.
Atea Pharmaceuticals press release
Atea Pharmaceuticals presents preclinical results supporting first-in-class potential of AT-587 for treatment of hepatitis E virus at CROI 2026
Atea Pharmaceuticals announced at CROI 2026 in vitro results showing that two proprietary oral nucleotide analogs, AT-587 and AT-2490, exhibit promising antiviral profiles as potential first-in-class inhibitors for the treatment of hepatitis E virus infection, a positive-sense, single-stranded RNA virus that primarily infects liver cells.
— SEE ALSO: Contagion Live: Antiviral emerges as a highly potent, first-in-class candidate for hepatitis E
Related HIV and Co-Infections News
-
Hepatitis B: Updates from Aligos Therapeutics, Arbutus Biopharma Corporation and Precision BioSciences
-
EurekAlert!: Between 2.4 and 4.1 million people estimated to be living with chronic hepatitis B infection in Europe
-
The Rockefeller University: A new mouse model of virus-driven liver cancer may open the door to better diagnosis and treatments
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.